The clinical innovation stems from the Phase 1 inMMyCAR study, which introduces KLN-1010, an experimental therapeutic agent developed by Kelonia Therapeutics. Diverging from traditional CAR-T cell protocols that necessitate the extraction and external engineering of T cells followed by re-infusion into patients, KLN-1010 employs an in vivo approach. This strategy generates chimeric antigen receptor T cells directly inside the patient’s body, thereby streamlining the therapeutic process, mitigating delays commonly associated with cell manufacturing, and obviating the need for lymphodepleting chemotherapy regimens that often precede CAR-T cell administration.

The in vivo gene placement system (iGPS) platform developed by Kelonia serves as the technological foundation underpinning KLN-1010. By leveraging advanced lentiviral vector delivery systems equipped with envelope modifications and tropism molecules, the platform achieves highly efficient and targeted transduction of T cells in situ. This platform-enhanced specificity fosters robust anti-tumor activity while minimizing off-target effects, thereby potentiating both the safety and effectiveness profiles of the therapy.

Winship Cancer Institute’s rapid activation as the second U.S. site in the global inMMyCAR trial and their distinction as the first institution to administer KLN-1010 on American soil highlight the institute’s leadership in accelerating access to cutting-edge clinical trials. This expedited trial deployment was facilitated through a concerted effort among multidisciplinary teams encompassing myeloma specialists, clinical operations, and research coordinators, emphasizing collaboration as key to cutting bureaucratic delays often hindering trial activation.

Multiple myeloma, a malignancy arising from plasma cells residing in bone marrow, remains challenging to treat despite recent therapeutic progress. Patients with relapsed or refractory forms face limited options and underscore an urgent need for novel therapies that can overcome resistance mechanisms. Traditional CAR-T treatments, although groundbreaking, are hampered by complex logistical challenges and toxicities related to preparative chemotherapy, factors that in vivo CAR-T therapies like KLN-1010 aim to resolve.

Preliminary data presented at the recent American Society of Hematology annual meeting provide a cautiously optimistic outlook, demonstrating encouraging early clinical responses and tolerability in the initial cohort of treated patients. While these findings kindle hope for improved outcomes, investigators underscore the investigational nature of the therapy, necessitating further longitudinal studies to ascertain durability of response and long-term safety implications.

Leading hematology experts at Winship have highlighted the transformative potential of this modality. The in vivo generative paradigm offers prospects for markedly reducing the time to treatment initiation and expanding patient accessibility, particularly for those who might otherwise be ineligible for cell collection or cannot tolerate traditional conditioning regimens. Such advancements could ultimately democratize CAR-T therapy, elevating it from a complex, resource-intensive intervention to a more routine and widely deployable treatment.

Kelonia Therapeutics continues to advance its pipeline using the iGPS platform to develop gene therapies across multiple indications, driven by the ambition to make CAR-T cell therapies accessible when and where patients need them. The successful deployment of KLN-1010 in this trial also sets a precedent for employing in vivo gene therapies in hematologic malignancies, propelling the field towards more patient-friendly, efficient, and scalable immunotherapeutic solutions.

The significance of Winship Cancer Institute’s role as Georgia’s sole National Cancer Institute-designated Comprehensive Cancer Center extends beyond delivering therapies. It provides a vital infrastructure to integrate breakthrough scientific discoveries into clinical care rapidly, fosters robust translational research, and cultivates an ecosystem where patients gain access to promising experimental treatments that might redefine standard-of-care paradigms.

In summary, the initiation of in vivo CAR-T therapy administration in the United States represents a pivotal inflection point in multiple myeloma treatment. It encapsulates the convergence of innovative gene delivery technologies, clinical expertise, and coordinated research efforts aimed at overcoming existing therapeutic barriers. Success in ongoing trials could herald a new era in oncology, wherein gene-modified immune cells are generated seamlessly within patients, offering safer, faster, and more accessible cancer immunotherapies.

Subject of Research: Investigational in vivo CAR-T cell therapy for relapsed and refractory multiple myeloma
Article Title: Winship Cancer Institute Administers First In Vivo CAR-T Therapy in U.S. for Multiple Myeloma
News Publication Date: May 13, 2026
Web References: https://www.keloniatx.com/
Keywords: in vivo CAR-T therapy, multiple myeloma, KLN-1010, chimeric antigen receptor T cells, Kelonia Therapeutics, in vivo gene placement system, phase 1 clinical trial, cancer immunotherapy, investigational therapy, lentiviral vector, hematologic malignancies, Winship Cancer Institute

A prominent highlight is the phase 3 randomized MajesTEC-9 study, which evaluates teclistamab monotherapy against the investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients suffering from relapsed refractory multiple myeloma. Co-authored by Dr. Carl O. Landgren, this trial underscores novel immunotherapeutic strategies aiming to improve outcomes in this notoriously challenging plasma cell disorder. The sophisticated study design integrates molecular response markers and clinical endpoints, providing robust evidence for teclistamab’s efficacy in heavily pretreated populations.

In gastrointestinal oncology, Dr. Jonathan Trent and colleagues have co-authored significant phase 1/1b and phase 3 trials assessing bezuclastinib combined with sunitinib versus sunitinib monotherapy, as well as velzatinib’s efficacy based on KIT mutation status in gastrointestinal stromal tumors (GISTs). These studies employ genomic profiling and pharmacokinetic modeling to optimize targeted treatment paradigms, emphasizing precision medicine approaches in managing advanced GIST, a malignancy characterized by heterogeneous mutational landscapes and treatment resistance.

Melanoma therapeutics are being advanced through multidisciplinary studies focusing on long-term survival correlations with cell-free DNA methylation biomarkers, as reported in the NIBIT-M2 trial led by Dr. Michele Ceccarelli. This research integrates epigenetic profiling with immunotherapy outcomes using nivolumab and ipilimumab, revealing intricate mechanisms of immune evasion and resistance in patients with brain metastases. Such findings have substantial implications for personalized surveillance and combination therapy optimization.

Sarcoma research, a relatively underexplored area, includes a pivotal phase 3 investigation of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS), co-authored by Dr. Jonathan C. Trent. Exploration of angiogenesis inhibitors and their impact on tumor microenvironments further deepens understanding of therapeutic resistance and offers potential for durable disease control in this rare sarcoma subtype.

The symposium on intercepting plasma cell disorders, featuring Dr. Rafat Abonour as a discussant, delves into the continuum from smoldering multiple myeloma to overt amyloid light-chain amyloidosis. This session underscores the transition phases of disease evolution and the critical windows for therapeutic intervention, emphasizing advanced diagnostic biomarkers and early therapeutic modalities designed to preempt clinical progression.

Cutting across multiple skin cancer forms, including uveal melanoma and nonmelanoma variants, Dr. Jose Lutzky presents novel insights into overcoming immunotherapeutic barriers through innovative clinical trials and molecular profiling. These studies investigate immune checkpoint blockade resistance mechanisms and aim to expand therapeutic responsiveness through biomarker-driven patient stratification.

Emerging in the field of adoptive cell therapy, Dr. Leonel F. Hernandez-Aya contributes to presentations on PRAME-directed T-cell receptor (TCR) therapies for advanced melanoma, elucidating patient-level clinical response dynamics. This research leverages high-throughput immune profiling and T-cell engineering techniques, pushing the envelope in personalized cancer immunotherapy.

Rapid oral presentations highlight pivotal findings such as the association of NAB2-STAT6 distal fusion with metastatic risk and thoracic tumor sites, spearheaded by Keerthana Sureshkumar. This genetic fusion acts as a biomarker for clinical prognosis, offering vital stratification tools for therapeutic decision-making. Additionally, global surveys on oncology physician career fulfillment and intent to leave, presented by Coral Olazagasti, provide essential data on workforce sustainability amidst increasing clinical demands, pointing to systemic issues in oncologic practice environments.

Expanding into real-world clinical practice, numerous poster presentations investigate diverse topics, ranging from AI decision-support algorithms for EGFR-mutant metastatic non-small cell lung cancer to the racial disparities in endometrial cancer survival post molecular classification. The integration of machine learning and bioinformatics into clinical oncology is a recurring theme, facilitating novel predictive models and personalized medicine frameworks.

Further studies illustrate the complex interplay between tumor genomics and treatment responses in sarcomas, leukemias, and pancreatic cancer, supported by extensive multi-institutional collaborations. These investigations refine the understanding of tumor heterogeneity and pave the way for biomarker-driven therapeutic strategies that aim to maximize efficacy while minimizing toxicity.

The special sessions offer strategic guidance for aspiring academic oncologists, featuring panels on publication artistry and career navigation, with experienced voices such as Dr. Mikkael Sekeres and Dr. Gilberto Lopes providing mentorship through shared experiences. These forums emphasize the importance of scholarly communication and international perspectives in advancing oncology careers and research dissemination.

Collectively, the Sylvester Comprehensive Cancer Center’s ASCO 2026 contributions represent a comprehensive showcase of transformative oncology research. Their work spans fundamental molecular insights, clinical trial innovations, real-world data integration, and educational leadership, marking significant strides toward precision oncology and improved patient outcomes across several malignancies. The multifaceted research agenda underscores a commitment to translating laboratory discoveries to clinical interventions, ultimately forging pathways for enhanced cancer care in the coming decade.

Subject of Research: Oncology clinical trials and biomarker-driven cancer therapeutic strategies presented by Sylvester Comprehensive Cancer Center at ASCO 2026.

Article Title: Groundbreaking Oncology Research from Sylvester Comprehensive Cancer Center at ASCO 2026 Redefines Cancer Therapeutics

News Publication Date: Not specified

Web References:

• Sylvester Comprehensive Cancer Center
• University of Miami Miller School of Medicine
• ASCO 2026 Annual Meeting

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: ASCO 2026, Sylvester Comprehensive Cancer Center, multiple myeloma, gastrointestinal stromal tumors, melanoma, sarcoma, plasma cell disorders, immunotherapy, targeted therapy, oncology clinical trials, biomarkers, cancer research

Multiple myeloma, a cancer of plasma cells, frequently develops resistance to current therapies, making relapsed and refractory forms of the disease particularly challenging for clinicians. Belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), has been studied extensively as an innovative therapeutic option. When paired with standard agents like bortezomib, a proteasome inhibitor, and dexamethasone, a corticosteroid, it harnesses a multi-pronged mechanism aimed at disrupting myeloma cell survival and proliferation.

The comprehensive exposure-response relationship studies reported by Papathanasiou and colleagues delve deeply into how varying concentrations of belantamab mafodotin correlate with efficacy endpoints and safety profiles. The advanced modeling techniques utilized were instrumental in distinguishing the optimal dose ranges that maximize tumor reduction while mitigating adverse events, a crucial balance in oncology therapeutics. Through this analysis, the investigators could dissect the nuanced interplay between drug exposure, tumor burden reduction, and treatment-emergent toxicities.

DREAMM-6 Arm B and DREAMM-7 trials enrolled patients with varying degrees of prior treatment exposure, providing a representative cohort mirrored to real-world clinical challenges. This diversity allowed the researchers to ascertain which pharmacological parameters most directly impact therapeutic success and to what extent the addition of bortezomib and dexamethasone could potentiate belantamab mafodotin’s antitumor activity. Such findings are invaluable in guiding treatment regimens in clinical practice.

An intriguing facet of the study was the examination of serum concentration profiles and their temporal relationship with clinical responses. By employing state-of-the-art population pharmacokinetic models, the researchers captured intricate dynamics such as interpatient variability and the impact of dosing intervals. These sophisticated analyses underscore the necessity of personalized medicine approaches whereby dosage can be tailored not just by body weight or surface area, but by an individual’s unique pharmacokinetic fingerprint.

Moreover, correlating exposure metrics with the incidence and severity of ocular adverse events, a known concern with belantamab mafodotin, illuminated potential mitigation strategies. Since corneal toxicities can significantly impair quality of life and reduce treatment adherence, understanding how these side effects relate to drug exposure guides clinical decision-making and patient monitoring. The study’s results pave the way for refined dosing schedules that balance potent anti-myeloma effects with manageable safety profiles.

The combination regimen exploits complementary mechanisms: bortezomib induces proteasome inhibition leading to apoptosis of myeloma cells, while dexamethasone exerts immunosuppressive and anti-inflammatory actions, collectively enhancing belantamab mafodotin’s cytotoxic efficiency. This multifaceted approach is critical in attacking resistant myeloma clones that often evade single-agent therapies. By quantifying exposure-response, the analysis provides empirical validation for the synergistic potential of this triplet therapy.

Clinicians confronting relapsed/refractory multiple myeloma often grapple with balancing efficacy against cumulative toxicities. The pharmacokinetic-pharmacodynamic insights from these DREAMM study arms equip them with precise information on how drug plasma levels translate to both tumor control and adverse events. Such detailed understanding fosters a paradigm where therapeutic regimens are not only efficacious but also patient-centric, minimizing undue harm through informed dose adjustments.

This study also offers a blueprint for future combination therapies involving antibody-drug conjugates and proteasome inhibitors. As the oncology field increasingly moves towards multi-agent regimens targeting diverse aspects of tumor biology, exposure-response analyses become indispensable tools. They afford a granular perspective on how new therapeutic agents integrate into the existing armamentarium, accelerating clinical adoption while safeguarding against unforeseen toxicities.

Another notable contribution of this research lies in its methodological rigor. The utilization of nonlinear mixed-effects modeling to analyze longitudinal pharmacokinetic and pharmacodynamic data exemplifies advanced quantitative pharmacology. This approach enables delineation of complex dose-exposure-efficacy-safety relationships, presenting a reproducible framework applicable beyond multiple myeloma to other malignancies and therapeutic modalities.

Furthermore, the translational implications extend into drug development pipelines. Data derived from these analyses can inform dose selection in subsequent phases of clinical trials, reducing attrition rates by preemptively identifying optimal dosing strategies. For belantamab mafodotin combinations, this means bolstering confidence in recommended regimens that balance patient benefit against manageable toxicity, ultimately expediting regulatory approvals and clinical implementation.

Patient stratification based on exposure-response metrics holds particular promise. Future iterations of this research could harness biomarker data alongside pharmacokinetic parameters to predict responders versus non-responders, facilitating precision oncology. Such stratified medicine would revolutionize treatment paradigms by sparing patients unlikely to benefit from unnecessary exposure while intensifying therapy for those predicted to achieve durable remissions.

The study’s emphasis on real-world applicability resonates strongly with current trends emphasizing pragmatic clinical research. By mirroring diverse patient populations and evaluating clinically relevant endpoints, the DREAMM-6 Arm B and DREAMM-7 analyses transcend theoretical pharmacology to offer actionable insights. This bridges the oft-noted gap between preclinical findings and bedside application, enhancing the therapeutic armamentarium for difficult-to-treat myeloma.

In summation, the exposure-response analyses for the combined use of belantamab mafodotin, bortezomib, and dexamethasone mark a seminal advancement in multiple myeloma therapy. By elucidating the pharmacologic underpinnings of dosing efficacy and adverse event profiles, these findings empower clinicians to deploy this potent triplet regimen with precision. As resistance to existing therapies looms large, such innovative strategies founded on robust scientific inquiry provide renewed hope for patients battling relapsed and refractory multiple myeloma.

As the oncology community digests these compelling results, ongoing research will undoubtedly refine and extend these findings. The dynamic interplay of antibody-drug conjugate pharmacology, proteasome inhibition, and corticosteroid therapy promises fertile ground for discovering optimal treatment schemas. Ultimately, this evolution in understanding heralds a new era where integrating exposure-response knowledge into clinical decision-making becomes routine, maximizing therapeutic potential for some of cancer’s most challenging forms.

Subject of Research:
Exposure-response analyses in the treatment of relapsed/refractory multiple myeloma using a combination of belantamab mafodotin, bortezomib, and dexamethasone.

Article Title:
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.

Article References:
Papathanasiou, T., Chen, X., Carreno, F. et al. Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03437-7

Image Credits: AI Generated

DOI: 13 April 2026